Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Compound was generated using a literature procedure and
2021-04-12

Compound was generated using a literature procedure and required two-step Dess–Martin-periodinane/Pinnick oxidation prior to the methylation of the sulfonamide. Compound () was obtained from the Suzuki coupling of the methyl ester intermediate (en route to YM 58483 australia ). Hydrolysis of all
-
br Discussion The membrane PVase
2021-04-12

Discussion The membrane PVase activity components were discriminated in this work by pre-incubating with PMSF, mipafox, paraoxon or PMSF + mipafox to irreversibly inhibitPVase activity to discriminate the enzymatic components, (EPα, EPβ, EPγ and EPδ). The concentrations employed to discriminate t
-
ku catalog receptor br Results and Discussion br Conclusion
2021-04-12

Results and Discussion Conclusion What we have shown here is that highly specific antagonist can be a very useful tool, can mimic gene KO experiments or even further dissect receptor function. We just took ETA antagonist as an example and found that ETA mediates physiological closure of DA whi
-
p and p which are
2021-04-10

p21 and p16, which are downstream of pAkt and pERK1/2, are tumor suppressors which induce cell senescence and ARCA Cy5 EGFP arrest [[56], [57], [58]]. Inhibitors of pAkt or pERK1/2 can activate p21 and p16 and promote cell senescence and cell cycle arrest [11,12,[59], [60], [61]]. It is well known
-
Aminothiazole derivatives have been reported to contain
2021-04-10

2-Aminothiazole derivatives have been reported to contain antiviral [17], anti-inflammatory [18], and antimicrobial [19] activities. The in vitro anticancer studies showed that different 2-aminothiazole derivatives possess selective and potent inhibitory effect against wide-ranging human cancerous c
-
br E intracellular localization br Regulation of E by
2021-04-10

E1 intracellular localization Regulation of E1 by other post-translational modifications Concluding remarks Acknowledgments We apologize to those whose work was not included because of space considerations or whose papers were unintentionally omitted. We thank Dr Peter Bullock (Tufts Uni
-
Herein the interactions of etamicastat nepicastat and zamica
2021-04-10

Herein, the interactions of etamicastat, nepicastat and zamicastat with P-gp and BCRP were evaluated. Although recent investigations have been performed to assess the involvement of P-gp in the 50014 mg exposure of nepicastat and etamicastat (Loureiro et al., 2015), the contribution of BCRP remains
-
Ezatiostat australia Aldehyde dehydrogenase has been charact
2021-04-10

Aldehyde dehydrogenase has been characterized as a cancer stem cell marker, which plays a key role in various biological processes in tumor, including cell proliferation, invasiveness and chemoresistance. Recent data of Abourbih et al reported that ALDH1 expression did not correlate with primary tum
-
Typical examples of CO utilization and reduction technologie
2021-04-10

Typical examples of CO2 utilization and reduction technologies are catalytic reduction of CO2 to C1 compounds such as CO, formic acid, methanol and so on [[3], [4], [5], [6], [7], [8], [9], [10]], and catalytic organic synthesis using CO2 as a feedstock [[11], [12], [13], [14], [15], [16], [17], [18
-
The aberrant methylation of genes that suppress tumorigenesi
2021-04-10

The aberrant methylation of genes that suppress tumorigenesis appears to occur early in tumor development and increase progressively, eventually leading to the malignant phenotype [35]. Genes involved in every step of tumorigenesis can be silenced by this epigenetic mechanism. Hypermethylation of pr
-
Mitophagy is a selective autophagic
2021-04-10

Mitophagy is a selective autophagic process which leads to the degradation of damaged mitochondria in response to metabolic or environmental stress conditions. In this study, we found that LFS-01 treatment significantly enhances p62 in a time-dependent manner. We found that the upregulation of p62 i
-
The H E staining and Nissl staining
2021-04-09

The H&E staining and Nissl staining results showed that damage to the pyramidal neurons in the CA1 and CA3 regions of the hippocampus were observed in the 50 mg/kg/day DBP group, accompanied by an absence of Nissl bodies, suggesting that DBP exposure can lead to pathological changes in the neurons o
-
ROS generation is crucial for NETs release
2021-04-09

ROS generation is crucial for NETs release upon both physiological or pathogenic stimuli [16,30]. In our study, we further verified this conclusion by demonstrating that SRA stimulation by Poly I enhanced intracellular ROS levels while scavenging of ROS by anti-oxidant agents effectively abolished t
-
AZD 2281 br Introduction The development of
2021-04-09

Introduction The development of non-melanoma skin cancer (NMSC) is a complex process characterized by the acquisition of altered proliferation and invasiveness. These changes are classically defined as occurring in stages, i.e., initiation, promotion, and progression. In the two-stage model of in
-
br Authors contribution br Disclosure statement br Acknowled
2021-04-09

Authors contribution Disclosure statement Acknowledgements This study has received funding from the Italian Ministry of University and Research (PRIN 2015, grant number 2015373Z39_008) and from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115797 (INNODIA)
16445 records 697/1097 page Previous Next First page 上5页 696697698699700 下5页 Last page